<DOC>
	<DOCNO>NCT01344109</DOCNO>
	<brief_summary>This pilot study evaluate use tumor derive exosomes marker response therapy woman receive neoadjuvant chemotherapy newly diagnose breast cancer . Tumor derive exosome analysis may novel diagnostic prognostic biosignature breast cancer , could prove tool earlier diagnosis , effective treatment , improve marker response order increase survival rate .</brief_summary>
	<brief_title>A Pilot Study Tumor-Derived Exosomes Diagnostic Prognostic Markers Breast Cancer Patients Receiving Neoadjuvant Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Women biopsy proven invasive carcinoma breast Women locally advance breast cancer breast tumor measure &gt; /= 2cm deem candidate preoperative chemotherapy Age &gt; /= 18 year old Expected survival &gt; /= 6 month Eastern Cooperative Oncology Group performance status 0 , 1 , 2 initiation study Initial require laboratory value : Absolute neutrophil count &gt; /= 1.5 x 10 ( 9 ) /L Platelet count &gt; /= 100,000 x 10 ( 9 ) /L Creatinine clearance &gt; /= 50mL/min ( calculate CockcroftGault method ) Liver function test ( AST , ALT , total bilirubin ) &lt; /= 2.5 x ULN Urine serum HCG negative ( female childbearing potential ) Women may enrol ongoing therapeutic preoperative chemotherapy trial No prior chemotherapy breast cancer No limitation prior radiation therapy No active , serious infection medical psychiatric illness likely interfere participation trial Nonpregnant nonnursing patient . Patients reproductive potential must agree use effective mean birth control No prior liver transplant bone marrow transplant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>